

OCT 03 2005

Applicant(s): S. Jayaraman
Application No.: 10/696,174
Examiner: S. Ghcrbi**Amendments to the Claims**

Please amend the claims as follows:

Listing of Claims

1. (currently amended) A method for treating a patient with an intravascular implant, the method comprising:

diagnosing the patient as having a vascular disease;

~~determining a prevalent disease process in the pathology of the vascular disease;~~

~~selecting a first agent to treat or prevent the prevalent disease process of the vascular disease;~~

coating at least a portion of the intravascular implant with a therapeutically effective amount of an inhibitor of mTOR;

coating at least a portion of the intravascular implant with a therapeutically effective amount of an inhibitor of PDGF receptor ~~the first agent~~; and

implanting the intravascular implant in the patient to treat the vascular disease.

2-7. (canceled)

8. (currently amended) A method as defined in claim 1 2 wherein coating at least a portion of the intravascular implant with the inhibitor of PDGF receptor includes coating at least a portion of the intravascular implant with a polymer matrix.

9. (currently amended) A method as defined in claim 8 wherein the polymer matrix includes a biostable or bioabsorbable polymer.

10. (canceled)

Applicant(s): S. Jayaraman
Application No.: 10/696,174
Examiner: S. Gherbi

11. (currently amended) A method as defined in claim ~~9~~ 10 wherein the therapeutically effective amount of the inhibitor of PDGF receptor ~~first agent~~ is dispersed within the biostable or bioabsorbable polymer.

12. (canceled)

13. (currently amended) A method as defined in claim ~~1~~ 12 wherein the intravascular implant includes a primer layer upon which at least one of the coatings ~~coating~~ is applied.

14-15. (canceled)

16. (currently amended) A method as defined in claim ~~1~~ 13 further including a top coat applied over at least one of the coatings ~~coating~~.

17-27. (canceled)

28. (currently amended) A method as defined in claim ~~1~~ 27, wherein coating the intravascular implant with the inhibitor of PDGF receptor and coating the implant with the inhibitor of mTOR ~~are~~ is performed at the procedure site and before the step of implanting the implant in the patient.

29-33. (canceled)

34. (new) A method as defined in claim 9, wherein the inhibitor of PDGF receptor is imatinib mesylate.

Applicant(s): S. Jayaraman
Application No.: 10/696,174
Examiner: S. Gherbi

35. (new) A method as defined in claim 34, wherein the imatinib mesylate is GLEEVEC.
36. (new) A method as defined in claim 1, wherein coating at least a portion of the intravascular implant with the inhibitor of mTOR includes coating at least a portion of the intravascular implant with a polymer matrix.
37. (new) A method as defined in claim 36, wherein the polymer matrix includes a biostable or bioabsorbable polymer.
38. (new) A method as defined in claim 37, wherein the therapeutically effective amount of the inhibitor of mTOR is dispersed within the biostable or bioabsorbable polymer.
39. (new) A method as defined in claim 37, wherein the inhibitor of mTOR is rapamycin.
40. (new) A therapeutic device for treating or preventing a disease of a patient, the device comprising an implant, an inhibitor of PDGF receptor disposed on the implant, and an inhibitor of mTOR disposed on the implant.
41. (new) A device as defined in claim 40 further including a polymeric coating associated with the implant, the polymer coating carrying the inhibitor of PDGF receptor.
42. (new) A device as defined in claim 41 wherein the polymeric coating includes a biostable or bioabsorbable polymer.
43. (new) A device as defined in claim 42 wherein the inhibitor of PDGF receptor is imatinib mesylate.

Applicant(s): S. Jayaraman
Application No.: 10/696,174
Examiner: S. Gherbi

44. (new) A device as defined in claim 43 wherein the imatinib mesylate is GLEEVEC.
45. (new) A device as defined in claim 40 further including a first polymeric coating associated with the implant, the first polymeric coating carrying the inhibitor of mTOR.
46. (new) A device as defined in claim 45 wherein the first polymeric coating includes a biostable or bioabsorbable polymer.
47. (new) A device as defined in claim 46 wherein the inhibitor of mTOR is rapamycin.
48. (new) A device as defined in claim 47 further including a second polymeric coating associated with the implant, the second polymeric coating carrying the inhibitor of PDGF receptor.
49. (new) A device as defined in claim 48 wherein the second polymeric coating includes a biostable or bioabsorbable polymer.
50. (new) A device as defined in claim 50 wherein the inhibitor of PDGF receptor is GLEEVEC.
51. (new) A device as defined in claim 51 wherein the implant is selected from the group consisting of a balloon catheter, stent, stent graft, drug delivery catheter, atherectomy device, filter, scaffolding device, anastomotic clip, anastomotic bridge, suture material, wire, embolic coil and a combination thereof.